MediciNova Takes a Big Step in the Fight Against COVID-19
MediciNova has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
MediciNova Inc. (NASDAQ: MNOV) has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally. The company’s shares jumped on Wednesday as a result.
Specifically, the firm announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen of SARS-CoV-2 in mice.
These successful results support the scientific and technical rationale of the intranasal vaccine, in addition to similar success with BioComo’s BC-PIV RSV vaccine prototype.
The vaccine prototype has proven highly efficient in its ability to transfer multiple foreign proteins to recipients. It also has a strong safety profile as no secondary infectious virus was produced.
[nativounit]
BC-PIV is designed to display not only the gene but also the foreign protein itself on the surface and inside of the viral membrane. Therefore, it can carry the large membrane proteins of viruses and signal transduction receptors/ligand proteins on the viral surface. The BC-PIV SARS-CoV-2 vaccine prototype has been developed to include the specific SARS-CoV-2 antigen protein in order to express maximum antigenicity.
Management stated that it was very encouraged by the intranasal vaccine and the results from the mouse model study. Again management is looking forward to reporting additional progress on its intranasal COVID-19 vaccine in the near future.
Excluding Wednesday’s move, MediciNova stock had underperformed the broad markets with about an 18% year-to-date retreat. In the past 52 weeks, the share price was down closer to 29%.
MediciNova stock traded up about 14% on Wednesday, at $6.33 in a 52-week range of $2.79 to $13.25. The consensus price target is $18.50.
[recirclink id=768967][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
